# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹220 Cr** Q3 FY26 (+9%) * **Gross Profit:** **+13% YoY** with **150 bps margin expansion** * **EBITDA:** **₹32 Cr** Q3 FY26 (sequential resilience, YoY pressure) * **PAT:** **₹4 Cr** Q3 FY26 (YoY decline due to front-loaded costs) * **Net Debt:** **₹680 Cr** standalone · **₹1,175 Cr** consolidated (as of Dec 2025) * Insurance Inflows: ₹83.48 Cr received · ₹251.12 Cr net receivable · ₹210 Cr expected by Mar 2026 ## B. Revenue Growth * **Resilient Demand:** Strong double-digit gross profit growth and margin expansion driven by robust volumes in Pharma, Flavors & Fragrances, and specialty chemicals. * **Capacity Constraints:** Revenue growth achieved despite temporary bottlenecks at Dahej facility, signaling upside potential upon resolution. * **Salt Monetization Pathway:** Salt and additive pricing **above $20/ton** supports future revenue potential of **over ₹1,000 Cr**, excluding electrolyte value-add. ## C. EBITDA & Profit * **Near-Term Cost Pressures:** EBITDA and PAT impacted by essential ramp-up costs at Neogen Ionics, fire-related expenses, and interim toll manufacturing—viewed as strategic investments. * **Financial Relief Ahead:** Near-term headwinds expected to ease with **insurance recoveries** under loss of profit policy, supporting future margin normalization. ## D. Net Debt Levels * **Debt Management Framework:** Standalone and consolidated net debt levels stable; **debtors and creditors expected to offset**, with target debtor days of **60–90 days** by year-end. * **Funding Strategy:** **70-30 debt-to-equity split** targeted post-separation; any funding gap to be covered by equity, with **promoter-led ₹150 Cr preferential issue** enhancing financial flexibility. * **Repayment Timeline:** Principal repayments for Dahej plant begin **Q1 FY28**, with interest under moratorium—no near-term cash outflow pressure. ## E. Cash Flow from Insurance * **Imminent Capital Inflows:** **₹60 Cr interim payment** expected within the week, and **₹150–170 Cr stock claim** anticipated by **March 2026**, driving near-term liquidity improvement. * **Pending Claims Resolution:** **₹140 Cr stock claim** under final audit review; disbursement likely by **March–April 2026**, while **loss of profit claims** to follow between **Sep–Dec 2026**. --- # 2. Product & Segment Performance ## A. Key Figures * **Battery Chemicals Revenue (Q3):** **₹12 Cr** contribution from Neogen Ionics * **CDMO Revenue Run Rate:** **₹800 Cr+** current run rate · **₹950 Cr** expected as operations scale * **Organic Chemicals Revenue:** **₹187 Cr** (+6% YoY) * **Inorganic Chemicals Revenue:** **₹33 Cr** (+35% YoY) ## B. Battery Chemicals Sales * **Strategic Positioning:** Neogen Ionics emerges as a cost-competitive global supplier of lithium salts and electrolytes, leveraging proven Japanese technology and securing long-term supply agreements. * **Growth Trajectory:** Transition to commercial scale underway, with value-based sales growth despite smaller volumes and rising interest in lithium intermediates. * **Revenue Momentum:** FY27 revenue forecast reflects robust demand visibility from key customers including Ola, Exide, and Waaree, with H2 expected to see acceleration. ## C. CDMO Segment Trends * **Resilient Performance:** CDMO segment held flat YoY in 9MFY26 despite Dahej facility outage, supported by Mahape and Karakhadi operations. * **Capacity Constraints:** Missed opportunities, including a semiconductor customer order, due to lack of specialized equipment and toll manufacturing reliance. * **Scaling Pathway:** Revenue run rate indicates strong base, with upside potential as Dahej resumes and production scales toward **₹950 Cr** target. ## D. Organic vs Inorganic * **Divergent Trends:** Inorganic chemicals surged on volume and strategic positioning, while organic derivatives faced mixed demand and product mix volatility. * **Price Sensitivity:** Decline in non-Neogen inorganic segment attributed entirely to falling lithium prices, with no operational deterioration. --- # 3. Manufacturing & Capacity ## A. Key Figures * **Dahej Expansion Capacity:** **1,100 tons** (completion Mar-2026) * **Total Salt Capacity:** **5,500 tons** (targeting >80% utilization by FY28) * **Neogen Planned Battery Capacity:** **30 GWh** (supports primary supplier positioning) ## B. Dahej Plant Status * **On-Track Rebuild with Delay:** Dahej replacement plant commissioning remains on track for **Q1 FY27**, though 1,100-ton expansion delayed to **March 2026** due to design refinements and training with Morita team. * **Bridge Strategy Effective:** Toll manufacturing successfully mitigated capacity bottlenecks, ensuring uninterrupted supply during reconstruction. * **Operational & Cost Benefits Ahead:** Shift to in-house production will eliminate tolling costs and improve cost structure, despite higher energy expenses; full operational status expected by **June 2026**. * **Revenue Ramp-Up Expected:** Salt-related revenue to begin in **Q1 FY26**, with significant ramp-up from **Q2 onward**, supported by audit approval by **June 2026**. * **Margin Tailwinds Building:** Performance improvement anticipated from **Q2/Q3 FY27** due to stabilized operations, lower insurance post-policy year, and tolling cost elimination. ## C. Pakhajan Project Timeline * **Commercial Launch Phased:** Pakhajan greenfield project on schedule, targeting **H1 FY27** for electrolyte and **H2 FY27** for salt commercial production, aligned with India’s ACC battery rollout. * **Early Output Possible:** Trial shipments of salt expected by **Q2 FY26** (targeting Sep-2026), with initial output in H2 FY27. * **Strategic Supplier Positioning:** Purpose-built scale makes Pakhajan attractive to new customers, though some may delay engagement by ~6 months; plant positions Neogen as a **primary supplier candidate** (e.g., Waaree). * **Limited FY27 Contribution:** Salt sales from Pakhajan not expected in Q4 FY27; ramp-up only in H2 FY27 implies minimal revenue contribution that year. * **Financial De-risking:** Q4 salt sales held as **backup** to offset Dahej or demand delays, supporting unchanged financial guidance. ## D. Capacity Utilization * **High Utilization Outlook:** Salt capacity utilization expected to reach **80% or higher** by FY28 on strong demand, while electrolyte plants can run up to **100%** due to formulation flexibility. * **Construction Momentum:** Equipment installed at Pakhajan, assembly underway, and trial production imminent. * **Capital Allocation Clarity:** Funds directed toward completing capex projects (partial loan drawdowns), working capital, and debt reduction. --- # 4. Customer & Approval Progress ## A. Key Figures * **Customer Approvals:** **Multiple global clients** granted provisional approval for lithium electrolyte salts, with final audits expected by **Q1 FY27** · **Three to four other customers** in active evaluation or sample approval stage * **Commercial Timeline:** Bulk consignments and regular production anticipated in **H1 FY27** · Final approvals across new and existing customers now expected by **June 2026** * **Supply Strategy:** **One or two** of three to four new customers may delay sourcing until Pakhajan commissioning; others to begin from **Dahej** · **Phased ramp-up** of supply expected starting **Q2/Q3 FY27** ## B. Global Client Approvals * **Momentum in Global Approvals:** Robust progress in securing provisional acceptances, with final site audits converging in early FY27, signaling strong validation of product quality and compliance standards. * **Diversified Customer Strategies:** US clients actively dual-sourcing ahead of schedule to de-risk China exposure, while price-sensitive buyers align transitions with regulatory deadlines in **Q4 FY27**. * **Complex but Manageable Approval Pathways:** Approval timelines vary by customer, with some requiring sequential site validations (Dahej → Pakhajan), while others opt to start directly at Pakhajan due to operational complexity. * **Customer Base Resilience:** Despite OEM JV exits, pipeline remains intact as decision-making authority rests with cell and electrolyte producers—key demand drivers unaffected by broader market shifts. ## C. Indian Giga-Factory Ties * **Anchor Domestic Win:** Secured long-term commercial supply approval from a major Indian giga-manufacturer post-PPAP clearance, establishing early-mover advantage in the domestic ecosystem. ## D. Audit & PO Pipeline * **Advanced Audit Stage:** Facility inspections for salt supply expected in **Jan–Feb 2026**, with required modifications nearly complete; biweekly engagement maintains alignment despite uncertain audit scheduling. * **Imminent Procurement Interest:** Most new customers express urgency to commence sourcing, with initial procurement planned from Dahej ahead of eventual transition to Pakhajan. * **POs Pending Site Progress:** Revised and repeat purchase orders, especially in CDMO, await customer visits starting **March 2026**, contingent on updated site readiness. * **Revenue Routing Note:** Some international Pakhajan salt sales may be channeled through NML, though **NIL** will remain the primary revenue-recognized entity in FY27. --- # 5. Joint Venture & Technology ## A. Key Figures * **JV Valuation:** **$100 million** (Neogen 80%, Morita 20%) * **Production Capacity:** **30,000 MT/year** (2,500 MT/month) across three lines post-trials ## B. Morita JV Integration * **Strategic Global Platform:** JV with Morita establishes Neogen Morita New Materials to produce LiPF6 salt globally, significantly expanding customer access and market reach. * **Asset & Ownership Clarity:** Morita’s 20% stake applies only to Pakhajan (salt business); Dahej (electrolyte business) remains 100% Neogen-owned. * **Funding Timeline:** Morita’s $20 million contribution expected by March/April 2026, contingent on regulatory separation approval. ## C. Japanese Technology Edge * **Technology-Led Differentiation:** Combines 30 years of proven Japanese tech with indigenous manufacturing, positioning Neogen as a leader in the global battery chemicals chain. * **Operational Readiness:** Backed by **1–2 years of commercial production experience** and lab-scale expertise, providing a head start over new entrants. * **Cost & Supply Advantage:** Backward integration strengthens cost efficiency and supply chain resilience versus peers. ## D. Mitsubishi Collaboration * **Quality Validation:** Partnership with top-tier Mitsubishi enhances product credibility and secures high-quality supply assurance. * **Capacity Ramp-Up:** Joint trials with Mitsubishi to validate all three production lines by end-H1, enabling full run-rate capacity. --- # 6. Risks & Regulatory Factors ## A. Customer Timing Risk * **No Impact from OEM Restructuring:** Company’s approval timelines and operations remain unaffected by restructuring activities at major US OEMs including **GM and Ford**. * **Volume Uncertainty Persists:** Electrolyte sales remain exposed to **customer plant commissioning schedules** and pending **regulatory approvals in Dahej**, both outside company control. * **Dynamic Customer Strategies:** Customer planning is inherently fluid, subject to shifting regulatory, operational, and market conditions. ## B. Regulatory Approval Delays * **Growth Financing Pending Approval:** Neogen’s **preferential issue**, intended to enhance financial flexibility for expansion, awaits regulatory clearance. * **Commissioning Delay Strategically Timed:** The deferral to **March 2026** was proactive, allowing full implementation of improvements pre-startup amid ongoing regulatory uncertainty. * **SEBI Clarification Pending:** A key **cooling-off period** issue related to the promoters’ family trust structure requires resolution under **SEBI guidelines**, despite its recognition within the promoter group. ## C. Chinese Supply Dependence * **Strategic Advantage from US-China Dynamics:** Non-FEOC provisions under **US 45X tax credits** and **Chinese price volatility** are boosting Neogen’s positioning as a preferred global partner. * **Limited Risk from Bromine Prices:** Business resilience maintained as most sales are under **long-term contracts**, with price pass-through only upon renewal and requiring **two- to threefold increases** to impact operations. * **Chinese Salt Stockpiling Not Viable:** US customers cannot circumvent 2027 restrictions on Chinese materials in batteries; **shelf life of salts (≤6 months)** and **current price parity or premium in China** further deter pre-buying. * **Lithium Price Impact Deferred:** Recent lithium cost increases in early 2026 will have **minimal effect on Q4 FY26 revenues**, as material inflows are expected only in **March or April 2026**. --- # 7. Guidance & Outlook ## A. Key Figures * **FY27 Battery Chemicals Revenue Guidance:** **₹400–500 Cr** (unchanged, slight delays expected) * **Target Quarterly Revenue Run Rate (Next FY):** **₹225–250 Cr** (up from current run rate towards ₹950 Cr annual target) * **Promoter Funding Commitment:** **₹150 Cr** via preferential issue (targeted by Mar-26) * **Total Expected Near-Term Funding:** **~₹550 Cr** (₹150 Cr promoter + ₹200 Cr partner + ₹200 Cr insurance) * **India Battery Capacity Target:** **12 GWh by end-2026**, **40–50 GWh by end-2027** ## B. FY27 Revenue Targets * **Guidance Intact Despite Delays:** FY27 battery chemicals revenue outlook maintained at ₹400–500 Cr despite **slight commissioning delays**; no material contribution expected from Pakhajan in FY27. * **Upside Optionality:** Pakhajan sales excluded from base case and treated as **backup capacity or upside**, contingent on Dahej ramp-up timing. * **Capacity vs. Output Divergence:** While **12 GWh of installed capacity** is targeted by end-2026, actual production may reach only **3–6 GWh** due to ramp-up variability. * **Revenue Trajectory Acceleration:** Targeted quarterly run rate of ₹225–250 Cr signals **step-up in revenue scaling** versus prior annual pace. ## C. Long-Term Growth View * **Robust Market Expansion Ahead:** India’s battery manufacturing capacity could grow to **40–50 GWh by end-2027**, driven by major expansions from Ola, Waaree, Reliance, and others. * **Base Business Growth Resumes:** **Double-digit revenue growth** expected in FY27–FY28 for core operations, supported by Dahej plant recovery and new project ramp. * **FY29 Revenue Uncertainty:** Long-term outlook hinges on **global demand for China-free supply chains** and Indian customers’ preference for **local LiPF6 vs. cheaper alternatives**. * **CDMO Growth Inflection:** Revenue acceleration in **CDMO and advanced intermediates** expected in FY27 post-new site commissioning. * **Lithium Price Impact Deferred:** Any **significant revenue uplift from high lithium prices** unlikely before FY27, contingent on price sustainability. ## D. Capital Availability * **Strong Promoter Backing:** In-principle approval for **₹150 Cr preferential issue** underscores promoter confidence; infusion expected by Mar-2026 or Q1 FY27. * **Multi-Source Funding Pipeline:** ~₹500–600 Cr in capital expected within six months via **insurance proceeds, JV partner funds, and internal accruals**. * **Insurance Proceeds Timing:** Full insurance realization expected between **September and December of the following year**; **third interim claim of ₹140 Cr** may be filed pre-March 2026.